Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6129546 | Clinical Microbiology and Infection | 2015 | 4 Pages |
Abstract
The water-soluble prodrug MCB3837 is rapidly converted to MCB3681, active against Gram-positive bacterial species, after intravenous infusion. The aim of this study was to prove the principle that MCB3681 is efficacious in vivo by demonstrating its effect on the resident microflora or colonizers of the human skin, nose, oropharynx and intestine. MCB3837 was infused at a daily dose of 6 mg/kg for 5 days. MCB3681 was active against clostridia, bifidobacteria, lactobacilli, enterococci and Staphylococcus aureus, thus proving the principle that MCB3681 is antibacterially efficacious in vivo without affecting the Gram-negative microflora.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
A. Dalhoff, M.-U. Rashid, T. Kapsner, G. Panagiotidis, A. Weintraub, C.E. Nord,